Sitagliptin (phosphate monohydrate)
Key facts
Invented name |
Tesavel
|
Active substance |
sitagliptin phosphate monohydrate
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0129/2016
|
PIP number |
Sitagliptin (phosphate monohydrate)
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Merck Sharp and Dohme (Europe), Inc.
|
Decision type |
PM: decision on the application for modification of an agreed PIP
|